33 results about "Cyclosporins" patented technology

The invention provides pharmaceutical compositions comprising about 0.05 to 0.1% (w / v) cyclosporine dissolved in 1-perfluorobutyl-pentane for use in the topical treatment of dry eye disease and provides for dosing and treatment methods thereof. The invention further provides kits comprising such compositions.

The application discloses a liposome drug carrier with mucosal adhesion, a preparation method and application thereof, and specifically, the drug carrier is DSPE-PEG-PBA, which can be used for loading cyclosporine A and crocin I, and the carrier of the application is used for loading cyclosporine A and crocin I. The liposome loaded with the two drugs has good stability and adhesion, can inhibit the side effect of cyclosporine A on the increase of ROS level, and has a wide application prospect in the treatment of inflammation and epithelial tissue damage.

The invention discloses a cyclosporin A combined self-assembly paclitaxel nano-drug and a preparation method and application thereof, and belongs to the field of biological medicine, the cyclosporin A combined self-assembly paclitaxel nano-drug is a nano-particle which is composed of paclitaxel, cyclosporin A and zinc ions and has a regular rod-like morphology, and the particle size of the nano-particle is 1-10 micrometers. The self-assembled paclitaxel nano-drug is prepared by combining cyclosporin A on the basis of a zinc ion coordinated supramolecular self-assembly strategy, so that the stability of the nano-drug can be improved, the toxic and side effects are reduced, the killing effect on drug-resistant tumors is enhanced, the approximate biological safety is retained, and the drug-resistant tumors are prevented from being damaged. The invention provides a new thought for overcoming the current situation of drug resistance of paclitaxel, and has important research value and wide application prospect.

The application belongs to the technical field of microorganisms, and particularly relates to a Fusarium solani strain for fermenting cyclosporin A, and further discloses application of the Fusarium solani strain for fermenting cyclosporin A. The application screens a Fusarium solani FIM-CS-66-69 strain for high-yield cyclosporin A by using an atmospheric pressure room temperature plasma mutagenesis technology, the Fusarium solani FIM-CS-66-69 strain can ferment cyclosporin A at a high yield, in a fermentation experiment, the Fusarium solani FIM-CS-66-69 strain can ferment cyclosporin A at a titer of 16551 ug / mL, the yield of cyclosporin A is greatly improved, and the content of homologues is low, so that the Fusarium solani FIM-CS-66-69 strain is more suitable for industrialized fermentation production.

This invention relates to the field of insect control, specifically to the Paecilomyces lilacinus strain XI-5, and the extraction and identification of crude toxins produced by secondary metabolites of Paecilomyces lilacinus strain XI-5. This invention confirms that the secondary metabolites of Paecilomyces lilacinus strain XI-5 produce cyclosporine C. Cyclosporine C has a stomach poison effect on adult whiteflies. Twenty-four hours after application, the LC50 concentration of cyclosporine C against adult whiteflies was 31.75 µg / ml; compared to the control group, the LC30 concentration of cyclosporine C resulted in a decrease in oviposition / fertility in female whiteflies.

The application discloses application of pulegone as an effective component in an immunosuppressant, and the pulegone with significant calcineurin (CN) inhibiting activity is screened from the Schleichera oleosa Kurz, the immunosuppressive effect of the pulegone is equivalent to that of cyclosporine A which is widely used in clinic, mechanism research shows that the pulegone targets CN / NFAT signal path to play the immunosuppressive activity, and the pulegone has very weak cytotoxicity to spleen cells, and is a high-efficiency and low-toxicity immunosuppressant.

Disclosed herein include methods, compositions, and kits suitable for use in preventing, treating or reverse fibrosis. The methods comprise administering to a subject in need thereof a composition comprising a cyclosporine analogue (for example, CRV431), or a pharmaceutically acceptable salt, solvate, stereoisomer thereof. The compositions and kits comprise a cyclosporine analogue (for example, CRV431), or a pharmaceutically acceptable salt, solvate, stereoisomer thereof.

The present invention provides a pharmaceutical composition which contains a population of cells, wherein the cells comprise cells that accumulate in an inflamed site and particles that are introduced into the cells and contain a bioabsorbable polymer and a drug, and the drug is cyclosporin or minoxidil.

This article discloses cyclosporine compounds and methods for treating or preventing neutrophil-mediated inflammation, wherein the compounds inhibit the activity of MRP2 and FPR1.

The invention provides pharmaceutical compositions comprising cyclosporine dissolved in a semifluorinated alkane for use in the treatment of uveitis.

Disclosed herein are cyclosporine compounds and methods for use in the treatment or prevention of neutrophil-mediated inflammation, wherein the compounds inhibit the activity of MRP2 and FPRL.

Disclosed herein include methods, compositions, and kits suitable for use in preventing, treating or reverse fibrosis. The methods comprise administering to a subject in need thereof a composition comprising a cyclosporine analogue (for example, CRV431), or a pharmaceutically acceptable salt, solvate, stereoisomer thereof. The compositions and kits comprise a cyclosporine analogue (for example, CRV431), or a pharmaceutically acceptable salt, solvate, stereoisomer thereof.

Provided herein are combinations comprising: 1) acoltremon; and 2) lifitegrast or cyclosporin, or a pharmaceutically acceptable salt thereof. The combinations are useful for treating dry eye or dysfunctional tear syndrome, or a sign or symptom thereof.

The present invention relates to a nanoemulsion ophthalmic composition and a preparation method thereof, wherein the nanoemulsion ophthalmic composition is obtained by mixing cyclosporine, castor oil, hydrophilic and hydrophobic emulsifiers, menthol, and an aqueous solvent, and thus exhibits excellent stability as well as ameliorating ocular irritation such as a feeling of grittiness, blurry vision, and the like.

The application discloses a cyclosporine A solid self-emulsifying drug composition and a preparation method thereof, and the drug composition comprises, in percentage by mass, 60-75% of a carrier material, 16.7-33.3% of a compatibility adjusting material, and the rest of cyclosporine A, and the sum of the mass percentages of all raw materials is 100%. The application is innovative in process from two aspects of selection of a compatibility adjusting material and a drug loading mode by developing a brand-new pre-molecularization-co-extrusion mode, and a ternary amorphous solid dispersion of cyclosporine A with strong compatibility and high stability is designed. The application fully utilizes the dissolution advantage of the amorphous solid dispersion technology, promotes the release of cyclosporine A, and simultaneously, due to the formation of a self-assembled sub-micro emulsion system, the intestinal permeability of cyclosporine A is significantly improved, and therefore, the application is a new preparation strategy which is safe and effective, green and environmentally-friendly, and has application prospects.

Provided herein are combinations comprising: 1) acoltremon; and 2) lifitegrast or cyclosporin, or a pharmaceutically acceptable salt thereof. The combinations are useful for treating dry eye or dysfunctional tear syndrome, or a sign or symptom thereof.

The present application relates to the field of nanoemulsions, in particular, cannabinoid-comprising nanoemulsions. The present disclosure provides cannabinoid (e.g., THC, CBD, CBDi or combinations of THC and CBD) comprising nanoemulsions that may optionally further comprise cyclosporine as methods of using the disclosed nanoemulsions to treat ophthalmic conditions such as dry eye. The disclosed formulations have significantly improved pharmaceutical stability in a variety of tested conditions when compared to conventional formulations.

A blood test method includes: a preparation step of preparing whole blood collected from a subject; a pretreatment step for preparing a sample for analysis by pretreating the whole blood; a separation step in which the sample for analysis is separated by components using a liquid chromatograph; and an analysis step for analyzing the separated component using a mass spectrometry device, the subject being administered with a first immunosuppressant comprising at least one substance selected from the group consisting of tacrolimus, cyclosporin A, everolimus, and sirolimus, and with a second immunosuppressant comprising at least one substance selected from the group consisting of cyclosporin A, everolimus, and sirolimus. The second immunosuppressive agent contains at least one substance selected from the group consisting of mycophenolic acids and metabolites thereof, the separated component contains the first immunosuppressive agent and the second immunosuppressive agent, and when the first immunosuppressive agent is analyzed as a target component in the analysis using the mass spectrometry device, the first immunosuppressive agent is separated from the target component, and when the second immunosuppressive agent is separated from the target component, the second immunosuppressive agent is separated from the target component. When the first immunosuppressive agent is analyzed as a target component, analysis is performed in a positive ion pattern, and when the second immunosuppressive agent is analyzed as a target component, analysis is performed in a negative ion pattern.

The present invention relates to a cyclosporine emulsion and preparation method thereof, in particular to an oil-in-water cyclosporine emulsion, comprising an interfacial stabilizer, wherein the interfacial stabilizer comprises a combination of polyethylene glycol 15-hydroxystearate and a phospholipid. The emulsion has long-term stability in terms of the pH value, particle size and encapsulation rate.

The present invention provides pharmaceutical compositions for the topical treatment of dry eye disease comprising about 0.05 to 0.1% (w / v) cyclosporin dissolved in 1-perfluorobutyl-pentane, and methods of administering and treating the same. The invention also provides kits comprising such compositions.

The invention relates to the field of albumin binding type drugs, in particular to a cyclosporin A entrapped albumin binding type drug as well as a preparation method and application thereof. The albumin binding type medicine comprises cyclosporin A or a derivative thereof and albumin, the mass ratio of the cyclosporin A or the derivative thereof to the albumin is 1: (1-10), and albumin molecules are connected through disulfide bonds formed by self-crosslinking of free sulfydryl of the albumin. The albumin combined medicine disclosed by the invention shows a remarkable curative effect in the aspect of treating xerophthalmia, and can be used for remarkably improving tear secretion and quality, effectively repairing corneal injury, relieving eye inflammation and promoting overall recovery of eye tissues. According to the albumin binding type medicine, the retention time of the medicine on the ocular surface can be remarkably prolonged, the local medicine concentration is improved, the eye tissue recovery is comprehensively promoted while symptoms are rapidly relieved, and good safety and potential clinical application value are shown.

Cyclosporine-eluting implants for treating a condition of the eye, and methods for their use, are disclosed herein. Also disclosed herein are methods for treating a condition of an eye of a subject. Also disclosed herein are methods of forming a system for treating a condition of an eye of a subject.

The present invention provides a dispersion composition comprising: a dispersion medium; and particles comprising a target substance. The dispersion composition comprises at least one surfactant at a concentration above the critical micelle concentration, and does not comprise a solubilizer. The target substance is cyclosporin A, and satisfies the previously defined S-parameter > 1.

The present invention belongs to the technical field of drug synthesis. In particular, the present invention is related to a for preparing a salt of isocyclosporin A, in particular by transesterification of cyclosporin A into a salt of isocyclosporin A.

Use of a combination of (a) cyclosporin H (CsH) or a derivative thereof, and (b) a p53 inhibitor and / or an adenoviral protein, or one or more nucleotide sequences encoding therefor, for increasing the efficiency of gene editing of an isolated population of cells when transduced by a viral vector and / or increasing the efficiency of transduction of an isolated population of cells by a viral vector.